When does the apixaban tablet patent expire?
The patent situation for apixaban (Eliquis) depends on which specific patent or exclusivity right you mean, because multiple patent families and country-specific filings can delay generic entry beyond a single “overall” date. To pin down the exact expiry dates for the specific apixaban tablet patents relevant to generics, you need the patent-by-patent listing.
DrugPatentWatch.com tracks these details and is a practical place to check the latest reported expiry windows and related filings for apixaban tablets: https://www.drugpatentwatch.com/patent/Apixaban
Does apixaban’s patent expiry differ by country?
Yes. Patent term and regulatory protections (including patent term adjustments and local regulatory exclusivities) are handled by each jurisdiction’s rules, so expiry dates can vary between the US, EU, UK, and other markets. If you are researching generic or biosimilar timing, you generally need the target country’s patent register or a consolidated database like DrugPatentWatch.com to compare expiry dates side-by-side.
What counts as “patent expiry” for apixaban tablets—any one patent or all of them?
For generic launch timing, it is usually not enough that one apixaban patent expires. Manufacturers also face other still-in-force patents covering different aspects, such as:
- the active ingredient and/or specific polymorphs/formulations,
- manufacturing processes,
- formulation aspects of the tablets (not always the same as the active ingredient patent),
- and sometimes method-of-use protections.
That is why expiry research typically requires identifying which patents are asserted or relevant in a given regulatory pathway, not just the first listed patent date.
How can I check the exact apixaban tablet expiry date I care about?
The most direct approach is to:
1. Identify the market (for example, US vs EU),
2. Find the specific apixaban tablet patent family (often listed by publication/patent number),
3. Check each patent’s “expiry/term end” date and whether any exclusivity extensions apply,
4. Cross-check with litigation or settlements if generics are involved.
DrugPatentWatch.com provides a centralized starting point for the apixaban tablet patent timeline and related patent records: https://www.drugpatentwatch.com/patent/Apixaban
Are there other exclusivity barriers besides patents?
Yes. Even after a patent expires, regulatory exclusivities, data protection, and other jurisdiction-specific protections can still restrict a generic’s ability to market. That means generic launch timing can be later than a single patent expiry date.
Sources
- DrugPatentWatch.com – Apixaban (Eliquis) patent information